Immune effectors required for the therapeutic activity of vorinostat.
作者信息
Kepp Oliver, Galluzzi Lorenzo, Kroemer Guido
机构信息
INSERM, U848; Villejuif, France ; Metabolomics and Cell Biology Platforms, Gustave Roussy; Villejuif, France ; Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers; Paris, France ; Université Paris Descartes/Paris V, Sorbonne Paris Cité; Paris, France.
Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers; Paris, France ; Université Paris Descartes/Paris V, Sorbonne Paris Cité; Paris, France ; Gustave Roussy; Villejuif, France.
出版信息
Oncoimmunology. 2013 Nov 1;2(11):e27157. doi: 10.4161/onci.27157. Epub 2013 Nov 13.
Abstract
摘要
相似文献
1
Immune effectors required for the therapeutic activity of vorinostat.伏立诺他治疗活性所需的免疫效应器。
Oncoimmunology. 2013 Nov 1;2(11):e27157. doi: 10.4161/onci.27157. Epub 2013 Nov 13.
2
Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal .白细胞介素 15 刺激的自然杀伤细胞在潜伏期逆转后清除 HIV-1 感染的细胞。
J Virol. 2018 May 29;92(12). doi: 10.1128/JVI.00235-18. Print 2018 Jun 15.
3
An intact immune system is required for the anticancer activities of histone deacetylase inhibitors.完整的免疫系统是组蛋白去乙酰化酶抑制剂发挥抗癌活性所必需的。
Cancer Res. 2013 Dec 15;73(24):7265-76. doi: 10.1158/0008-5472.CAN-13-0890. Epub 2013 Oct 24.
4
Structural Requirements of Histone Deacetylase Inhibitors: SAHA Analogs Modified on the Hydroxamic Acid.组蛋白去乙酰化酶抑制剂的结构要求：基于异羟肟酸修饰的SAHA类似物
Arch Pharm (Weinheim). 2016 May;349(5):373-82. doi: 10.1002/ardp.201500472. Epub 2016 Apr 9.
5
Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T cell and natural killer cell lymphoma.丁酸钠对 EBV 相关 T/NK 细胞淋巴瘤的抗肿瘤作用。
Cancer Sci. 2014 Jun;105(6):713-22. doi: 10.1111/cas.12418. Epub 2014 May 13.
6
Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis.组蛋白去乙酰化酶抑制剂丙戊酸和伏立诺他增强曲妥珠单抗介导的抗体依赖细胞介导的吞噬作用。
J Immunother Cancer. 2020 Jan;8(1). doi: 10.1136/jitc-2019-000195. Epub 2020 Jan 2.
7
The histone deacetylase inhibitor suberoylanilide hydroxamic acid attenuates human astrocyte neurotoxicity induced by interferon-γ.组蛋白去乙酰化酶抑制剂 SAHA 可减轻干扰素-γ诱导的人星形胶质细胞神经毒性。
J Neuroinflammation. 2012 May 30;9:113. doi: 10.1186/1742-2094-9-113.
8
The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.组蛋白去乙酰化酶抑制剂的结构要求：C4修饰的SAHA类似物具有HDAC6/HDAC8双重选择性。
Eur J Med Chem. 2018 Jan 1;143:1790-1806. doi: 10.1016/j.ejmech.2017.10.076. Epub 2017 Oct 31.
9
Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.伏立诺他是一种组蛋白去乙酰化酶（HDAC）抑制剂，可促进细胞周期停滞，并使利妥昔单抗和化疗耐药的淋巴瘤细胞对化疗药物重新敏感。
J Cancer Res Clin Oncol. 2016 Feb;142(2):379-87. doi: 10.1007/s00432-015-2026-y. Epub 2015 Aug 28.
10
Molecular sequelae of histone deacetylase inhibition in human malignant B cells.组蛋白去乙酰化酶抑制对人恶性B细胞的分子后遗症
Blood. 2003 May 15;101(10):4055-62. doi: 10.1182/blood-2002-11-3514. Epub 2003 Jan 16.
引用本文的文献
1
The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors.表观遗传免疫调节剂HBI-8000可增强反应并逆转对检查点抑制剂的耐药性。
BMC Cancer. 2021 Aug 30;21(1):969. doi: 10.1186/s12885-021-08702-x.
2
Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody.胰腺肿瘤先前暴露于 [索拉非尼+伏立诺他] 可增强抗 PD-1 抗体的疗效。
Cancer Biol Ther. 2019;20(1):109-121. doi: 10.1080/15384047.2018.1507258. Epub 2018 Aug 24.
3
A broad-spectrum antibiotic, DCAP, reduces uropathogenic Escherichia coli infection and enhances vorinostat anticancer activity by modulating autophagy.广谱抗生素 DCAP 通过调节自噬减少泌尿道致病性大肠杆菌感染并增强伏立诺他的抗癌活性。
Cell Death Dis. 2018 Jul 13;9(7):780. doi: 10.1038/s41419-018-0786-4.
4
Novel chemoimmunotherapeutic strategy for hepatocellular carcinoma based on a genome-wide association study.基于全基因组关联研究的肝细胞癌新型化免疫治疗策略。
Sci Rep. 2016 Dec 2;6:38407. doi: 10.1038/srep38407.
5
Trial Watch: Proteasomal inhibitors for anticancer therapy.试验观察：用于抗癌治疗的蛋白酶体抑制剂
Mol Cell Oncol. 2014 Dec 1;2(2):e974463. doi: 10.4161/23723556.2014.974463. eCollection 2015 Apr-Jun.
6
An autophagy-dependent anticancer immune response determines the efficacy of melanoma chemotherapy.一种自噬依赖性抗癌免疫反应决定了黑色素瘤化疗的疗效。
Oncoimmunology. 2014 Jul 3;3(7):e944047. doi: 10.4161/21624011.2014.944047. eCollection 2014.
7
Classification of current anticancer immunotherapies.当前抗癌免疫疗法的分类。
Oncotarget. 2014 Dec 30;5(24):12472-508. doi: 10.18632/oncotarget.2998.
8
Epigenetic enzymes are the therapeutic targets for CD4(+)CD25(+/high)Foxp3(+) regulatory T cells.表观遗传酶是CD4(+)CD25(+/高)Foxp3(+)调节性T细胞的治疗靶点。
Transl Res. 2015 Jan;165(1):221-40. doi: 10.1016/j.trsl.2014.08.001. Epub 2014 Aug 15.
9
Immunogenic cell death inducers as anticancer agents.作为抗癌剂的免疫原性细胞死亡诱导剂
Oncotarget. 2014 Jul 30;5(14):5190-1. doi: 10.18632/oncotarget.2266.
本文引用的文献
1
An intact immune system is required for the anticancer activities of histone deacetylase inhibitors.完整的免疫系统是组蛋白去乙酰化酶抑制剂发挥抗癌活性所必需的。
Cancer Res. 2013 Dec 15;73(24):7265-76. doi: 10.1158/0008-5472.CAN-13-0890. Epub 2013 Oct 24.
2
Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance.常规和靶向抗癌疗法的作用机制：重新激活免疫监视。
Immunity. 2013 Jul 25;39(1):74-88. doi: 10.1016/j.immuni.2013.06.014.
3
The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures.癌症免疫监视的连续性：预后、预测和机制特征。
Immunity. 2013 Jul 25;39(1):11-26. doi: 10.1016/j.immuni.2013.07.008.
4
Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells.组蛋白去乙酰化酶抑制剂下调激活型 NKp30 配体 B7-H6，从而损害 NK 细胞对肿瘤细胞的识别。
Blood. 2013 Aug 1;122(5):684-93. doi: 10.1182/blood-2013-02-482513. Epub 2013 Jun 25.
5
Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines.体液免疫反应对蒽环类药物介导的抗肿瘤作用的贡献。
Cell Death Differ. 2014 Jan;21(1):50-8. doi: 10.1038/cdd.2013.60. Epub 2013 Jun 7.
6
HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy.组蛋白去乙酰化酶抑制可抑制原发性免疫反应，增强次级免疫反应，并在肿瘤免疫治疗期间消除自身免疫。
Mol Ther. 2013 Apr;21(4):887-94. doi: 10.1038/mt.2012.265. Epub 2013 Jan 8.
7
Anticancer activity of cardiac glycosides: At the frontier between cell-autonomous and immunological effects.强心苷的抗癌活性：在细胞自主和免疫效应之间的前沿。
Oncoimmunology. 2012 Dec 1;1(9):1640-1642. doi: 10.4161/onci.21684.
8
Enhancing the antitumor effects of radiotherapy with combinations of immunostimulatory antibodies.联合免疫刺激抗体增强放射治疗的抗肿瘤作用。
Oncoimmunology. 2012 Dec 1;1(9):1629-1631. doi: 10.4161/onci.21652.
9
Tumor-infiltrating B cells and T cells: Working together to promote patient survival.肿瘤浸润 B 细胞和 T 细胞：协同作用，促进患者生存。
Oncoimmunology. 2012 Dec 1;1(9):1623-1625. doi: 10.4161/onci.21650.
10
Radiotherapy supports protective tumor-specific immunity.放疗支持保护性的肿瘤特异性免疫。
Oncoimmunology. 2012 Dec 1;1(9):1610-1611. doi: 10.4161/onci.21478.
Zotero 插件